How do sirolimus-eluting and paclitaxel-eluting stents compare in patients with and without diabetes mellitus?
Antonio Colombo
Correspondence EMO Centro Cuore Columbus, via M. Buonarroti 48, 20145 Milan, Italy
Email colombo@emocolumbus.it
This article has no abstract so we have provided the first paragraph of the full text.
There is a critical need to improve outcomes after PCI in patients with diabetes. Drug-eluting stents (DESs) are supposed to provide the most benefit in patients with diabetes because this population has a higher incidence of cardiac death and need for a second procedure when balloon angioplasty or bare-metal stents (BMSs) are used. At present, two DESs have demonstrated superiority compared with BMSs in a general population of patients: the Cypher® stent and the Taxus® stent.1 When the question of DES efficacy is focused on patients with diabetes, two statements can be made: first, whatever difference might exist in outcomes between these two stents, the difference is clinically marginal (a different answer would have been evident by now); and second, we await a DES that is more effective in patients with diabetes.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
